Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Azzalure, Restylane/Emervel filler, and Restylane Skinbooster for facial aesthetic improvement
2014-001203-50Phase 4Completed
- Sponsor
- Q-Med
- Start
- May 2014
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-blind trial of botulinum toxin type A, hyaluronic acid + lidocaine and Restylane Skinboosters Vital + lidocaine in None (3 arms), sponsored by Q-Med. Primary endpoint: Superior global facial aesthetic appearance at 1 month after first combined treatment. Started May 2014; status: completed.
02
Drugs
botulinum toxin type Ahyaluronic acid + lidocaineRestylane Skinboosters Vital + lidocaine
Beyond the preview
Go deeper on 2014-001203-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001203-50.